A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2 2025 год

more

A.I. Burnasyan  FMBC clinical bulletin. 2022 № 4

N.I. Kurysheva, S.G. Sergushev, O.A. Pererva

Retinal Vein Occlusions Treatment Approaches: Review

A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia

Contact person: Pererva Oksana: Oxana.pererva@yandex.ru

Abstract
Retinal vein occlusion (RVO) is the second among acquired vascular eye diseases, giving priority only to diabetic retinopathy. The severity of retinopathy depends on the location of the occlusion and the development of collateral vessels. RVO is not accompanied only by a decrease in visual acuity (VA), but also by the development of such complications as recurrent intravitreal hemorrhages, traction retinal detachment, secondary neovascular glaucoma. It causes the disability of patients and loss of professional fitness in people of working age. The treatment of RVO focuses on two main goals. The first one is the identification of risk factors and their drug therapy, and the second one is the identification and treatment of complications of retinal vein occlusion. The treatment of any pathology depends on early diagnosis, as well as a quick and well-chosen algorithm for managing the patient. The macular edema is treated by intravitreal injections of corticosteroids, antiVEGF, laser photocoagulation of the retina. Intraocular injections is currently the only way to provide a high intravitreal and intraretinal concentration of the drug. This review describes an algorithm for choosing the optimal treatment for RVO.

Keywords: retinal vein occlusion, macular edema, neovascularizations

For citation: Kurysheva NI, Sergushev SG, Pererva OA. Retinal Vein Occlusions Treatment Approaches: Reviews. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2022.4:18-25. (In Russian) DOI: 10.33266/2782-6430-2022-4-18-25


REFERENCES

  1. Danilichev V.F. Obosnovaniye i Effektivnost Primeneniya Proteoliticheskikh Fermentov pri Patologii Glaz (Kliniko-Eksperimentalnoye Issledovaniye) = Justification and Effectiveness of the Use of Proteolytic Enzymes in Eye Pathology (Clinical and Experimental Study): Avtoref. diss. … doct. med. nauk. 1983. P. 24 (In Russ.).
  2. Oh J.O., Minasi P., Grabner G., Ohashi Y. Suppression of Secondary Herpes Simplex Uveitis by Cyclosporine. Invest. Ophthalmol. Vis. Sci. 1985;26;4:494-500.
  3. Brown C.A. Penicillin in Ophthalmology: The Bacteriological, Experimental, and Clinical Evidence of Its Value, Including a Personal Series of 125 Clinical Cases. Br. J. Ophthalmol. 1946;30;3:146-167.
  4. Sorsby A., Ungar J. Intravitreal Injection of Penicillin; Study on the Levels of Concentration Reached and Therapeutic Efficacy. Br. J. Ophthalmol. 1948;32;12:857-864. DOI:10.1136/bjo.32.12.857.
  5. Voronin G.V., Budzinskaya M.V., Strakhovskaya M.G., Khalatyan A.S. Antibiotic Resistance in Patients after Serial Intravitreal Injections. Vestnik Oftalmologii = The Russian Annals of Ophthalmology. 2019;3:109-112 (In Russ.).
  6. Yin V.T., Weisbrod D.J., Eng K.T., et al. Antibiotic Resistance of Ocular Surface Flora with Repeated Use of a Topical Antibiotic after Intravitreal Injection // JAMA Ophthalmol. 2013. V.131, No. 4. P. 456-461. DOI:10.1001/jamaophthalmol.2013.2379.
  7. Miño De Kaspar H., Hoepfner A.S., Engelbert M., et al. Antibiotic Resistance Pattern and Visual Outcome in Experimentally-Induced Staphylococcus Epidermidis Endophthalmitis in a Rabbit Model. Ophthalmology. 2001;108;3:470-478. DOI:10.1016/s0161-6420(00)00545-5.
  8. Benoist d’Azy C., Pereira B., Naughton G., Chiambaretta F., Dutheil F. Antibioprophylaxis in Prevention of Endophthalmitis in Intravitreal Injection: A Systematic Review and Meta-Analysis. PLoS One. 2016;11;6:e0156431. DOI:10.1371/journal.pone.0156431.
  9. Ferguson A.W., Scott J.A., McGavigan J., et al. Comparison of 5% Povidone-Iodine Solution Against 1% Povidone-Iodine Solution in Preoperative Cataract Surgery Antisepsis: a Prospective Randomised Double Blind Study. Br. J. Ophthalmol. 2003;87;2:163-167. DOI:10.1136/bjo.87.2.163.
  10. Deramo V.A., Lai J.C., Fastenberg D.M., Udell I.J. Acute Endophthalmitis in Eyes Treated Prophylactically with Gatifloxacin and Moxifloxacin. Am. J. Ophthalmol. 2006;142;5:721-725. DOI:10.1016/j.ajo.2006.05.044.
  11. Miller D., Flynn P.M., Scott I.U., Alfonso E.C., Flynn H.W. Jr. In Vitro Fluoroquinolone Resistance in Staphylococcal Endophthalmitis Isolates. Arch. Ophthalmol. 2006;124;4:479-483. DOI:10.1001/archopht.124.4.479.
  12. Pożarowska D., Pożarowski P. The Era of Anti-Vascular Endothelial Growth Factor (VEGF) Drugs in Ophthalmology, VEGF and Anti-VEGF Therapy. Cent. Eur. J. Immunol. 2016;41;3:311-316. DOI: 10.5114/ceji.2016.63132.
  13. Good T.J., Kimura A.E., Mandava N., Kahook M.Y. Sustained Elevation of Intraocular Pressure after Intravitreal Injections of Anti-VEGF Agents. Br. J. Ophthalmol. 2011;95;8:1111-1114. DOI:10.1136/bjo.2010.180729.
  14. Mansour A.M., Shahin M., Kofoed P.K., et al. Insight Into 144 Patients with Ocular Vascular Events During VEGF Antagonist Injections. Clin. Ophthalmol. 2012;6:343-363. DOI:10.2147/OPTH.S29075.
  15. SooHoo J.R., Seibold L.K., Kahook M.Y. The Link between Intravitreal Antivascular Endothelial Growth Factor Injections and Glaucoma. Curr. Opin. Ophthalmol. 2014;25;2:127-133. DOI:10.1097/ICU.0000000000000036.
  16. Dedania V.S., Bakri S.J. Sustained Elevation of Intraocular Pressure after Intravitreal Anti-Vegf Agents: What Is the Evidence? Retina. 2015;35;5:841-858. DOI:10.1097/IAE.0000000000000520.
  17. Neely D.C., Bray K.J., Huisingh C.E., Clark M.E., McGwin G.Jr., Owsley C. Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care. JAMA Ophthalmol. 2017;135;6:570-575. DOI:10.1001/jamaophthalmol.2017.0830.
  18. Brown D.M., Campochiaro P.A., Bhisitkul R.B., et al. Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. Ophthalmology. 2011;118;8:1594-1602. DOI:10.1016/j.ophtha.2011.02.022.
  19. Ciulla T.A., Huang F., Westby K., Williams D.F., Zaveri S., Patel S.C. Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States. Ophthalmol Retina. 2018;2;7:645-653. DOI:10.1016/j.oret.2018.01.006.
  20. Aref A.A.. Management of Immediate and Sustained Intraocular Pressure Rise Associated with Intravitreal Antivascular Endothelial Growth Factor Injection Therapy. Curr. Opin. Ophthalmol. 2012;23;2:105-110. DOI:10.1097/ICU.0b013e32834ff41d.
  21. Kiddee W., Montriwet M. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents. PLoS One. 2015;10;9:e0137833. DOI:10.1371/journal.pone.0137833.
  22. Xiong Q., Li Z., Li Z., et al. Anti-VEGF Agents with or Without Antimetabolites in Trabeculectomy for Glaucoma: a Meta-Analysis. PLoS One. 2014;9;2:e88403. DOI:10.1371/journal.pone.0088403.
  23. Campochiaro P.A., Marcus D.M., Awh C.C., et al. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. Ophthalmology. 2019;126;8:1141-1154. DOI:10.1016/j.ophtha.2019.03.036.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 11.11.2022. Accepted for publication: 30.09.2022

© 2025 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top